Oculis HoldingOCS
About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Employees: 36
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0.76% less ownership
Funds ownership: 7.98% [Q2] → 7.22% (-0.76%) [Q3]
7% less capital invested
Capital invested by funds: $39.8M [Q2] → $36.9M (-$2.82M) [Q3]
9% less funds holding
Funds holding: 11 [Q2] → 10 (-1) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 77%upside $30 | Buy Reiterated | 11 Nov 2024 |
Financial journalist opinion
Based on 3 articles about OCS published over the past 30 days